The CDK4/6 inhibitor palbociclib, the BCL2 inhibitor venetoclax, and the ERBB2 inhibitor lapatinib did not change the transcriptional expression of estrogen receptors (ER, PR) or estrogen response markers (GREB1 TFF1, TFF3) in FA organoids (Supplementary Fig. 16). Here, BCL2 is linked to Friedreich ataxia.